Skip to content

Clinical trials

Completed Major Depressive Disorder trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Major Depressive Disorder Status: Completed Country / region: United States Clear all

1,007 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
200112
200225
200328
200435
200535
200662
200744
200851
200944
201056
201173
201250
201337
201447
201548
201644
201747
201836
201925
202035
202147
202234
202330
202424
20257

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed1,007

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Massachusetts General Hospital55
National Institute of Mental Health (NIMH)47
Eli Lilly and Company37
New York State Psychiatric Institute37
Forest Laboratories27
University of California, Los Angeles26
Otsuka Pharmaceutical Development & Commercialization, Inc.23
Mclean Hospital22
Stanford University22
Janssen Research & Development, LLC20

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Major Depressive Disorder1,007
Bipolar Disorder93
Depressive Disorder87
Mood Disorders57
Anxiety Disorders49
Schizophrenia44
Psychotic Disorders42
Stress Disorders, Post-Traumatic37
Depressive Disorder, Treatment-Resistant35
Mental Disorders34

Trials

Showing 1 to 25 of 1,007. Each trial links to its page on Pharma Observatory.

907 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.